This site is intended for healthcare professionals

Phase III INCREASE study of Tyvaso meets primary endpoint in pulmonary hypertension with interstitial lung disease.- United Therapeutics

Read time: 1 mins
Published:25th Feb 2020
Condition: Pulmonary Arterial Hypertension/ PH + ILD
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest